You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Smoking May Transform Relapsing-Remitting MS Into Secondary Progressive MS

  • Authors: News Author: Laurie Barclay, MD
    CME Author: Désirée Lie, MD, MSEd
  • CME Released: 4/27/2005
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 4/27/2006
Start Activity


Target Audience and Goal Statement

This article is intended for primary care physicians, neurologists, and other specialists who care for patients at risk of or with MS.

The goal of this activity is to provide the latest medical news to physicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  • Describe the association between smoking and MS.
  • Examine the risk of secondary progression of MS associated with smoking.


Disclosures

As an organization accredited by the ACCME, Medscape requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as "financial relationships in any amount, occurring within the past 12 months," that could create a conflict of interest.


Author(s)

  • Laurie Barclay, MD

    Laurie Barclay is a freelance reviewer and writer for Medscape.

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.

Reviewer(s)

  • Gary Vogin, MD

    Senior Medical Editor, Medscape

    Disclosures

    Disclosure: Gary Vogin, MD, has disclosed no relevant financial relationships.

CME Author(s)

  • Desiree Lie, MD, MSEd

    Clinical Professor of Family Medicine; Director, Division of Faculty Development, University of California, Irvine School of Medicine, Irvine, California

    Disclosures

    Charles Vega, MD, FAAFP, has disclosed that he has received grants for educational activities from Pfizer.


Accreditation Statements

    For Physicians

  • Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Medscape designates this educational activity for 0.25 category 1 credit(s) toward the AMA Physician's Recognition Award. Each physician should claim only those credits that reflect the time he/she actually spent in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Smoking May Transform Relapsing-Remitting MS Into Secondary Progressive MS

Authors: News Author: Laurie Barclay, MD CME Author: Désirée Lie, MD, MSEdFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 4/27/2005

Valid for credit through: 4/27/2006

processing....

April 27, 2005 — Smoking increases the risk of progression of multiple sclerosis (MS), according to the results of a study published in the March 9 Advanced Access issue of Brain.

"Compared with non-smokers, smokers had a 40-80% increased risk of multiple sclerosis in the four previously conducted prospective studies (all restricted to women)," write Miguel A. Hernán, MD, from the Harvard School of Public Health, in Boston, Massachusetts, and colleagues. "On the other hand, there are no epidemiological studies on the association between cigarette smoking and the clinical course of multiple sclerosis. Since no modifiable risk factors for multiple sclerosis progression have been identified so far, determining whether cigarette smoking affects the course of multiple sclerosis appears to be a priority."

The investigators identified patients with a first diagnosis of MS recorded in the British General Practice Research Database (GPRD) between January 1993 and December 2000. They confirmed the diagnosis and date of first symptoms by medical record review and obtained smoking status from the computer database.

To evaluate the association between smoking and MS risk, they conducted a case-control study nested in the GPRD, randomly selecting up to 10 control subjects per case. Matching was on the basis of age, sex, practice, date of joining the practice, and availability of smoking data. A cohort study of MS cases with a relapsing-remitting onset helped determine the association between smoking and progression of MS.

In the nested case-control study, which included 201 cases of MS and 1,913 controls subjects, the odds ratio (OR) of MS was 1.3 (95% confidence interval [CI], 1.0 - 1.7) for "ever smokers" compared with "never smokers." In the cohort study, with 179 cases and mean duration of follow-up of 5.3 years, the hazard ratio of secondary progression was 3.6 (95% CI, 1.3 - 9.9) for ever smokers compared with never smokers.

"These results support the hypothesis that cigarette smoking is associated with an increased risk of multiple sclerosis, and suggest that smoking may be a risk factor for transforming a relapsing-remitting clinical course into a secondary progressive course," the authors write. "We also confirmed previous findings indicating that smokers have a moderately increased risk of developing multiple sclerosis compared with non-smokers."

Study limitations may include possible confounding by other lifestyle factors or differential adherence to treatment by smoking status.

"The growing body of epidemiological evidence on the association between smoking and multiple sclerosis warrants further investigation," the authors conclude. "This line of research may provide some clues into the pathogenesis of multiple sclerosis and perhaps new insights into the prevention of the disease and its progressive forms."

The National Multiple Sclerosis Society funded this research.

Brain. Posted online March 9, 2005.